Ideaya Biosciences

This early-phase study tests a new drug called IDE034 in about 150 adults with advanced solid tumors (like lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can sh…

This early-phase study tests a new drug called IDE892, alone or with other treatments, in people with advanced solid tumors (like lung, stomach, bladder, or pancreatic cancer) that have a specific genetic change called MTAP deletion. The main goals are to check safety and find th…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This study tests a new drug called IDE574 in people with advanced solid tumors or a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study has two parts: first, testing IDE574 alone in various cancers; second, combining it…

This study tests a new drug, IDE849, in people with small cell lung cancer or other tumors that have a protein called DLL3. The goal is to see if the drug is safe and can shrink tumors. About 208 participants will receive IDE849 alone or with other treatments. This is an early-st…

This phase 3 trial tests the drug darovasertib given before standard surgery for people with a type of eye cancer called uveal melanoma that hasn't spread. The goal is to see if the drug can prevent vision loss and help patients keep their eye instead of needing it removed. About…